ArticleCancer cell international2026
Integrative analysis of SLFN11-related DEGs reveals novel biomarkers for cisplatin sensitivity and immune modulation in colorectal cancer.
Article in Cancer cell international, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
5 authors.
Funding
Abstract
backgroundCisplatin is a widely used chemotherapy drug, but resistance mechanisms, including the role of SLFN11, pose significant challenges in colorectal cancer (CRC) treatment, with only 15-20% of patients showing objective responses.
methodsWe conducted differential gene expression analysis using datasets GSE181094, GSE179896, and GSE231559, alongside TCGA-COAD and TCGA-READ datasets. DEGs were identified using DESeq2, Limma, and edgeR, followed by protein-protein interaction network analysis with STRING, and functional enrichment analysis via KEGG, GO, and GSEA. Mendelian randomization (MR) analysis was performed using the TwoSampleMR package with robust instrumental variable validation, and single-cell RNA sequencing data was analyzed using Seurat and SingleR to examine cell-type specific expression patterns.
resultsOur analysis identified several DEGs, including FOXL1 and GPC4, associated with cisplatin sensitivity in SLFN11 knockout cell lines. MR analysis revealed SLC46A3 as a significant gene related to CRC, showing a causal relationship (β=-0.2935, p = 0.0308). Single-cell RNA sequencing demonstrated high expression of SLFN11 in granulocyte-monocyte progenitor and common myeloid progenitor cells in adjacent normal tissues, with reduced expression in cancerous tissues. These findings highlight the significant impact of SLFN11 on gene expression and its potential as a biomarker for cisplatin sensitivity.
conclusionSLFN11 plays a critical role in modulating cisplatin sensitivity in CRC, with implications for personalized cancer therapy. These findings establish SLFN11 as a potential biomarker for personalizing cisplatin-based therapies in CRC patients, potentially improving response rates and clinical outcomes.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.